Scarica l'app Stockscreener
9.415
0.59%
0.065
Dopo l'orario di chiusura:
9.44
0.025
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia
Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria
Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan
Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance
What analysts say about Viatris Inc. stockExponential wealth increase - Autocar Professional
Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News
Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha
What to Expect From Viatris' Next Quarterly Earnings Report - MSN
What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com
Is Viatris Inc. a good long term investmentExplosive capital appreciation - jammulinksnews.com
VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN
Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq
Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance
Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter
Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest
Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest
Trend Tracker for (VTRS) - news.stocktradersdaily.com
Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss By Investing.com - Investing.com South Africa
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - Yahoo Finance
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga
Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com
Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's
Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest
Why Is Viatris Stock Falling In Pre-market? - Nasdaq
Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha
Viatris eye ointment fails late-stage study, shares fall - TradingView
Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com
Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com India
Viatris eye therapy fails to meet late-stage trial goal - TradingView
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire
Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN
Viatris (VTRS) Receives a Hold from Goldman Sachs - The Globe and Mail
Hypopituitarism Treatment Market Expansion Supported - openPR.com
Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest
Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha
Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN
0.31%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):